Lynparza – pharmaceutical daily

March 16, 2022 Off

Lynparza Reduced Risk of Death by 32% in the Adjuvant Treatment of Patients with Germline BRCA-mutated High-risk Early Breast Cancer

Further positive results from the OlympiA Phase III trial showed AstraZeneca and MSD’s Lynparza (olaparib) demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS) versus placebo in the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) high-risk human epidermal growth factor receptor 2 (HER2)-negative early breast cancer who had completed local treatment and standard neoadjuvant or adjuvant chemotherapy.

November 5, 2020 Off

AstraZeneca’s olaparib + bevacizumab cleared as certain cancer treatment in EU

By Dino Mustafić

AstraZeneca and MSD’s Lynparza (olaparib) has been approved in the European Union (EU) for the 1st-line maintenance treatment with bevacizumab of patients with homologous recombination deficient (HRD)-positive advanced ovarian cancer.

May 11, 2020 Off

Myriad gets FDA approval of myChoice CDx as companion diagnostic for Lynparza

By Dino Mustafić

Te U.S. Food and Drug Administration (FDA) approved the myChoice CDx test for use as a companion diagnostic by healthcare professionals to identify certaikn advanced ovarian cancer patients.

May 11, 2020 Off

Lynparza approved in US as with bevacizumab for HRD-positive advanced ovarian cancer

By BusinessWire

AstraZeneca’s and Merck’s Olaparib, Lynparza has been approved in US as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer, the companies said Monday in a press release.

May 8, 2020 Off

LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer

By BusinessWire

Improved the Median Time to Disease Progression (37.2 months) vs. Bevacizumab Alone (17.7 months) Following Response to Platinum-Based Chemotherapy with…

April 25, 2020 Off

– AZ, Merck say Lynparza useful in test for mCRPC

By BusinessWire

AstraZeneca and Merck revealed further positive results from the Phase 3 PROfound trial evaluating LYNPARZA in men with metastatic castration-resistant prostate cancer (mCRPC).

September 30, 2019 Off

LYNPARZA (olaparib) More Than Doubled the Time Without Radiographic Disease Progression in Patients With BRCA1/2- or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer

By BusinessWire

AstraZeneca and Merck’s LYNPARZA reduced the risk of disease progression or death by 51% in men with homologous recombination repair…

August 14, 2019 Off

LYNPARZA meets Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer

By BusinessWire

AstraZeneca and Merck’s LYNPARZA when added to standard-of-care bevacizumab significantly increased the time women lived without disease progression or death…

June 19, 2019 Off

Lynparza approved in Japan for 1st-line maintenance therapy in BRCA-mutated advanced ovarian cancer

By Dino Mustafić

AstraZeneca and Merck revealed Wednesday that Lynparza (olaparib) has been approved in Japan as a maintenance treatment after 1st-line chemotherapy in patients with BRCA-mutated (BRCAm) advanced ovarian cancer, the only PARP inhibitor approved in Japan .

June 19, 2019 Off

The approval of BRACAnalysis for women with ovarian cancer in Japan

By Dino Mustafić

Japanese Ministry of Health, Labour, and Welfare has granted a second manufacturing and marketing approval for Myriad Genetics’ subsidiary, Myriad Genetic Laboratories, for BRACAnalysis Diagnostic System as a companion diagnostic with the PARP inhibitor, Lynparza, marketed by AstraZeneca and Merck.